Antipsychotic Long-acting Injections

by Peter Haddad (Editor), Tim Lambert (Editor), John Lauriello (Editor)

Overview

Antipsychotic Long-acting Injections (LAIs) were introduced in the 1960s to improve treatment adherence in schizophrenia. Subsequently, first-generation antipsychotic LAIs became widely used in many countries. Since the initial publication of Antipsychotic Long-acting Injections in 2010, new trial data have been published on long-acting injection (LAI) preparations of the drugs Risperidone, Paliperidone, and Olanzapine. Furthermore, a new LAI preparation of the drug Aripiprazole has recently been approved for clinical use in the United States and is likely to be approved in Europe soon. The second edition of this successful book has been fully updated to include this new data, with reference to both observational studies and randomized controlled trials, as well as other new developments in the clinical use of antipsychotic LAIs. New chapters have been added covering the comparison between oral and injectable antipsychotics, Olanzapine LAI, Aripiprazole LAI, and the practicalities of organizing a specialized clinic for long-acting injectable antipsychotics. Existing chapters have also been thoroughly updated to take into account the most recently published research. Antipsychotic Long-acting Injections, Second edition brings together clinical and research findings on LAIs in a comprehensive volume, with chapters written by international experts.

Product Details

ISBN-13:	9780191045783
Publisher:	OUP Oxford
Publication date:	05/10/2016
Sold by:	Barnes & Noble
Format:	eBook
Pages:	320
File size:	3 MB

About the Author

Dr Peter Haddad is Consultant Psychiatrist at Greater Manchester West Mental Health NHS Foundation Trust, UK and Honorary Clinical Professor of Psychiatry at the University of Manchester, UK. He has a major clinical and research interest in pharmacological treatment of major mental illnesses (depression, bipolar disorder, schizophrenia) including adherence. He is also interested in improving the physical health of those with serious mental illness. Professor Tim Lambert is Professor of Psychiatry at Concord Clinical School at The University of Sydney in Australia. He also holds an appointment as Head of Schizophrenia Treatment and Outcomes Research at the Brain&Mind Research Institute in Sydney. In addition, he fulfils clinical duties for Sydney Local Health Network as Director of the Centre of Excellence in Relapse Prevention in Psychosis (CERP), and at the Concord Centre for Cardiometabolic Health in Psychosis (ccCHiP). His current interests focus on services research (pharmacoepidemiology, developing novel relapse prevention, treatment resistance, and cardiometabolic services for the seriously mentally ill); the clinical pharmacology of LAI antipsychotics (first and second generation) and of the second-generation antipsychotics, particularly risk-benefit aspects and the applied clinical pharmacology of antipsychotic switching; physical comorbidities of psychotic disorders, especially cardiometabolic syndromes; and incomplete recovery. Professor John Lauriello is Professor and Chair of the Department of Psychiatry, University of Missouri, School of Medicine, Columbia, Missouri, USA. He specializes in the diagnosis and treatment of psychotic disorders, most notably schizophrenia.

Table of Contents

1. Antipsychotic treatment and adherence in schizophrenia, Christoph U. Correll, Chris Abbott, Samuel J. Keith, and Peter Haddad
2. Pharmacology of antipsychotic long-acting injections, Tim Lambert and David Taylor
3. Adverse effects and antipsychotic long-acting injections, Peter Haddad and W. Wolfgang Fleischhacker
4. Comparative effectiveness of oral antipsychotics and Long-acting Injectable Antipsychotics, Taishiro Kishimoto, Christoph U. Correll, and John M. Kane
5. First-generation antipsychotic long-acting injections, Mark Taylor and Polash Shajahan
6. Risperidone Long-acting Injection, Pierre Chue
7. Paliperidone Long-Acting Injection, Muaid Ithman, Niels Beck, and John Lauriello
8. Olanzapine long-acting injection, Dieter Naber, Daniel Luedecke, and Daniel Schottle
9. Aripiprazole Long Acting Injectable, Ganesh Gopalakrishna, W. Wolfgang Fleischhacker, and John Lauriello
10. Long-acting injectable antipsychotics in early psychosis, Robin Emsley, Bonga Chiliza, and Laila Asmal
11. Health professionals' and patients' attitudes to LAIs, Maxine X. Patel
12. Patient choice and long-acting injectable medication, Mary Jane Tacchi, Jennifer Nendick, and Jan Scott
13. Prescribing patterns and determinants of use of antipsychotic long-acting injections: an international perspective, Tim Lambert
14. The management of a specialist clinic for long acting injectable antipsychotics, Tim Lambert
15. The role of antipsychotic long-acting injections in clinical practice, Peter Haddad, Tim Lambert, and John Lauriello

Editorial Reviews

Reviewer: Aaron John Plattner, MD (Network180 )
Description: Long-acting antipsychotics have a distinct place in the treatment options for those with schizophrenia and bipolar disorder. This second edition of a complete review of these medications updates the 2011 edition.
Purpose: The book discusses when long-acting injectable medications would be an appropriate treatment consideration. Given the high frequency of antipsychotic medication noncompliance and psychiatric hospitalization readmission rates combined with what could be strongly argued is a low rate of use of long-acting antipsychotic medications, this book is needed. The authors accomplish their goal of educating their readers about long-acting antipsychotics.
Audience: The authors are vague in describing their target audience as "a range of healthcare professionals" and, while this is certainly true given that many primary care providers are treating very ill psychiatric patients, psychiatric residents and attending psychiatrists would likely benefit the most, particularly those whose practice involves community mental health and/or inpatient psychiatric care. The editors are credible authorities in this area and they sought out experts from across the globe to contribute.
Features: The book not only describes the specific forms of long-acting antipsychotic injections using research findings, it also examines the background behind the need, limitations, and social factors of these medications. Chapters examine the attitudes of mental health providers regarding long-acting antipsychotics, factors that influence patient choice for long-acting antipsychotics, and management of a clinic that provides long-acting antipsychotic medications. Each chapter contains various graphics to help readers better understand the material (specifically research findings) and ends with references. A helpful index concludes the book.
Assessment: I was impressed by the unparalleled high quality of the first edition of this book, which is only improved upon in this update. As an inpatient psychiatrist, I have often used the first edition as a reference and have directed residents to read chapters related to patient care. This edition is updated with new research data and additional chapters to enhance its use.

Doody's Review Service